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ABSTRACT 
Objective: The present investigation is aimed to develop and validate, a simple, consistent and sensitive stability-indicating reverse phase-high 
performance liquid chromatography (RP-HPLC) method for the determination of oral anti-diabetic drug Canagliflozin in bulk and pharmaceutical 
dosage form as per the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH-Q2 (R1)).  
Methods: The chromatographic separation was achieved by using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) ZORBAX 
C18 (250 mm x 4.6 mm, 5μm particle size) with a mobile phase consisting of Acetonitrile: Water in a ratio of 53:47% v/v at a flow rate of 1 ml/min 
with an injection volume of 20 μl.  
Results: The Retention time of the drug Canagliflozin was found to be 2.36±0.05 min and detected at 214 nm UV wavelength. The linear regression 
equation was found to be y = 60702x–2156.2 with a correlation coefficient 0.9999. Stress degradation studies were performed by exposing the 
Canagliflozin into acidic, alkaline, oxidative, thermal and photolytic stress conditions with active samples withdrawn at different time intervals as 
per ICH guidelines. 
Conclusion: The proposed Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) method was found to be robust, precise and 
specific for estimation of Canagliflozin in pharmaceutical dosage forms. 
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INTRODUCTION 
Canagliflozin (C24H25FO5S) is chemically namedas(2S,3R,4R,5S,6R)-2-
[3-[[5-(4-fluoro phenyl) thiophen-2-yl] methyl]-4-methylphenyl]-6-
(hydroxymethyl)oxane-3,4,5-triol; hydrate, physical appearance of it 
is a white to off white solid with melting range of 95-105 °C It has 
good solubility nature in few organic solvents (methanol, Dimethyl 
sulfoxide) but poorly soluble in aqueous media [1].  
Canagliflozin is a novel oral anti-diabetic agent which belongs to a 
newly developed class Sodium-glucose co-transporter-2 (SGLT2) 
Inhibitor. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are 
typically expressed in proximal renal tubules and is responsible for 
90% re-absorption of glucose which is initially filtered by kidneys. 
Sodium-glucose co-transporter 2 (SGLT2) lower the reabsorption of 
filtered glucose into the body and decreases the renal threshold for 
glucose (RTG), leading to incremented urinary glucose excretion. 
Therefore, the inhibitors of SGLT2 have been emerged as novel 
therapeutic approach for type 2 diabetes mellitus (T2DM) [2-6]. 
Canagliflozin (CNZ) is the first SGLT2 inhibitor approved for 
glycemic control in adults with T2DM. U. S. Food and Drug 
Administration (US FDA) approved this drug in March-2013 for 
treating patients having type-II diabetes [7]. 
 
 
Fig. 1: Structure of canagliflozin 
In various chromatography methods, flow rate and detectors plays a 
major role in the detection of Canagliflozin, such as fluorescence 
detector used in estimating the drug in plasma HPLC-FLD [8], Diode 
Array Detectors HPLC-PDA [9-14]. Various analytical techniques 
involved in the estimation of the drug-like Ultra-High-Performance 
Liquid Chromatography-Mass Spectroscopy UHPLC-MS in biological 
fluids like human and rat plasma[15], Densitometric analysis of 
Canagliflozin HPTLC Method [16], Double beam Ultraviolet 
Spectroscopic method [17, 18]. 
Bio-analytical assay conducted to estimate the drug in plasma by 
researchers; they utilized various techniques for separating the drug 
from plasma, Sample extracted by liquid-liquid extraction method 
[19], protein precipitation method [20, 21]. Even good 
chromatographic separation is achieved by ion-pair buffers in 
reverse-phase liquid chromatography.  
Limited number of research work available for HPLC-UV detector. In 
this study, we focused on developing new quality control method to 
estimate and validate as per ICH guidelines. 
MATERIALS AND METHODS 
Chemicals and reagent 
For this study, we Utilized HPLC grade Acetonitrile of Rankem 
Limited, India and HPLC grade water of SD fine-Chem ltd; Mumbai. 
Marketed samples of Canagliflozin (Prominad 100 mg tablets) were 
purchased from a local chemist shop. 
Instrumentation 
Schimadzu LC 2010 HPLC system supplied with a gradient pump 
connected to Ultra-violet detector set at 214 nm used. Lab solution 
software (Version) was used for data acquisition and for system 
suitability calculations. A 0.001 gm sensitive electronic analytical 
weighing balance Schimadzu BL-220H and an Ultra-sonicator 
(Equibtron) were used in this study. Thermal stability studies were 
carried out in an I-Therm dry air oven. 
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Optimized chromatographic conditions 
Chromatographic separation was attained on ZORBAX C18 (250×4.6 
mm, 5 µm) column using mobile phase composition of Acetonitrile 
and Water in the ratio of 53:47% (v/v). The mobile phase was 
filtered and degassed through 0.45μm HPLC Millipore filter paper. 
The Flow rate was kept at 1.0 ml/min for the entire study; injection 
volume of 20 µl, column temperature of 30 °C, the detector 
wavelength of 214 nm, were set for the chromatographic study.  
Preparation of stock solution 
Accurately weighed quantity of Canagliflozin (100 mg) standard 
powder into a 100 ml volumetric flask, dissolved and diluted up to 
the mark with diluent and was ultra-sonicated for 5 min to get 1 
mg/ml solution of Canagliflozin (1000 μg/ml). Further dilutions 
were made as per the requirement by dissolving it in diluent and 
filtered through 0.45μm and degassed before injection. 
Preparation of mobile phase 
The mobile phase composition of Acetonitrile and water in the ratio 
of 53:47 (%v/v) was prepared by mixing 530 ml of Acetonitrile and 
470 ml of water. In this experiment, we utilize the mobile phase as 
diluent. 
Method validation 
The developed method was validated for different prescribed 
parameters like accuracy, specificity, linearity, precision, robustness, 
Limit of Detection (LOD) and Limit of Quantification (LOQ) as per 
guidelines of ICH Q2A and Q2B [22-23]. 
Linearity 
A series of solutions over the range of 2,4,6,8,10,12,20,40,80,100 and 
120 μg/ml for Canagliflozin were prepared and 20μl of each solution 
was injected into HPLC system and peak area of the chromatogram 
was noted. Calibration curve was plotted against the concentration 
of the solutions on the x-axis and corresponding peak area on the y-
axis.  
Precision 
Precision studies conducted at three levels: Repeatability, 
Intermission and Reproducibility. Repeatability was carried out by 
analyzing the sample at Intra and Interday. Inter-day variation was 
analyzed by selecting minimum three concentrations of the analyte 
which were 4, 8 and 12 μg/ml. Intra-day analysis was carried on 
same day, whereas Interday analysis was carried on three different 
days in replicates of three at the different schedule time. The 
respective peak areas for different concentrations of Interday and 
Intraday were reported and % Relative Standard Deviation (RSD) 
was calculated. 
Accuracy 
Accuracy method was carried out by standard addition method in 
which standard addition of Canagliflozin at three different 
concentration levels of 80%, 100% and 120% was performed in 
triplicate. Recovery studies carried out by preparing different 
concentration solution of Canagliflozin (80%, 100% and 120 %) by 
adding 3.2µg/ml, 4µg/ml and 4.8µg/ml into 4µg/ml (100%) solution 
of three replicate drug samples. Accuracy of the method is calculated 
by calculating the % recovery of the Canagliflozin as per the ICH 
guidelines. 
Robustness 
Changing the following method parameters flow rate (±0.2 ml/min), 
temperature (±2%), mobile phase (±2%) and wavelength (±2 nm) 
determines the robustness of the selected method. A 4μg/ml 
solution of Canagliflozin was taken and 20μl was injected into the 
HPLC system to measure its peak area for conducting robustness 
study. 
Limit of detection (lod) and limit of quantification (LOQ) 
A limit of detection (LOD) and a limit of quantification (LOQ) were 
calculated according to the formula:-LOD = 3.3 σ/s and LOQ = 10 σ/s 
Where, ‘σ’ is the standard deviation of the response‘s’ is the slope of 
the calibration curve. LOD and LOQ determine the sensitivity of the 
developed method. 
Stress degradation studies 
The stability-indicating property of the developed HPLC method 
carried out by stress studies as per ICH recommended conditions. 
Stress degradation of Canagliflozin was carried out by forcefully 
subjecting the bulk sample into acidic, alkaline, oxidative, photolytic 
and thermal conditions. To study the ability of the developed 
method is to measure the analyte response in the presence of its 
degraded products due to stress applied in different conditions [10]. 
All solutions utilized for this study was diluted from the stock 
solution prepared and kept with the concentration of 1000μg/ml. 
Stock solutions further refluxed for 20 min at 80 °C conditions. 
Sample solution prepared as per the requirement by diluting it with 
mobile phase.  
Acidic degradation 
Acidic degradation was performed by taking 0.4 ml of stock solution 
and treating it with 9 ml of 0.1N HCl for 1 hour in a thermostat 
maintained at 80 °C in laboratory conditions. The stressed sample 
was cooled, neutralized with 0.1N NaOH and then diluted with 
Mobile phase as per the requirement. Diluted solution of 20μl was 
injected into the HPLC system and its peak area was measured. 
Alkali degradation 
Alkali degradation performed by taking 0.4 ml of stock solution and 
treating it with 9 ml of 0.1N NaOH for 1 hour in a thermostat 
maintained at 80 °C in laboratory condition. The stressed sample 
was cooled, neutralized with 0.1N HCl and then diluted with Mobile 
phase as per the requirement. Diluted solution of 20μl was injected 
into the HPLC system and its peak area measured. 
Oxidation 
10 ml of the stock solution was taken and transferred into 100 ml 
round bottom flask. The contents were then mixed with oxidative 
agent 30% H2O2 90 ml. The reaction mixture was allowed to proceed 
at high temperature (80 °C) for at least 2 h with intermittent 
shaking. Then 4 ml of the above solution was cooled and then 
diluted with 10 ml mobile phase as per the requirement. A volume of 
20 µl was injected into the HPLC system to measure peak height, 
peak area and retention time. 
Irradiation with ultraviolet light 
100 mg sample powder of Canagliflozin was exposed to UV light 
(254 nm) for 2 d in neat and clean surface. After the exposure period 
the material was dissolved in 100 ml Mobile phase. Then the 
solution was filtered with 0.45 µm using syringe filtration disk. It 
was suitably diluted to get 40 ppm of Canagliflozin and a volume of 
20 µl was injected into the HPLC system to measure peak height, 
area and retention time.  
Thermal degradation 
A sample powder of Canagliflozin (100 mg) was exposed to a 
thermal energy in a hot air oven at a temperature of 80 °C for 48 h. 
Then the sample material was dissolved in 100 ml Mobile phase, the 
solution was filtered with syringe filtration disk claimed 
concentration of 1 mg/ml. Further dilution made to get 40 ppm of 
Canagliflozin standard solution. Repeat the same procedure for 
Tablet Canagliflozin and then 20 µl Standard and Sample solution 
injected into the HPLC system to measure peak height, area and 
retention time. 
Assay of marketed formulation (Tablets) 
Weigh and take 20 Canagliflozin tablet, and triturated to and fro to 
get fine powder. A 100 mg equivalent weight was taken in a 100 ml 
volumetric flask containing 10 ml mobile phase. The flask is then 
ultra-sonicated for 20 min and make up the volume with methanol. 
The tablet sample solution is then filtered through whatman filter 
paper (No. 41) and from the above solution 10 ml is diluted to 10 ml 
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with diluents so as to get 100µg/ml for the assay. The 0.4 ml of 
resulting solution B was again filtered and then diluted with 10 ml 
mobile phase to get Canagliflozin (4µg/ml). Inject 20 µl was injected 
into the HPLC system to measure peak height, area and retention 
time. 
RESULTS AND DISCUSSION 
Method development and optimization 
Chromatographic elution of Canagliflozin by reverse-phase liquid 
chromatographic Method was performed with different trials for 
optimization of chromatographic condition amide at faster analysis 
and less time-consuming determination of Canagliflozin. Satisfactory 
separation and good peak symmetry was observed for Canagliflozin with 
the mobile phase consisting of Acetonitrile: water (53:47% v/v), using 
ZORBAX C18 (250×4.6 mm, 5 µm), with the flow rate of 1.0 ml/min, 
detected at 214 nm. The retention time was observed at 2.36 min, 
theoretical plate (N) 2753 and US tailing (Tf) 0.99 factors was within the 
acceptance criteria. The chromatogram of the blank, Standard (STD) 
Canagliflozin and Tablet Canagliflozin was showed in fig. 2. 
 
 
Fig. 2: Chromatogram of canagliflozin in optimized condition 
 
Method validation 
For the Linearity study, series of Canagliflozin solution were primed in 
the concentration range of 2-12µg/ml, 20μl, 40 µl, 80μl, 100μl and 120μl 
(fig. 3). The Linearity graph was plotted against peak area vs. 
concentration. The correlation coefficient of regression value, intercept 
value was calculated using the formula y=60702x–2156.2 (r2=0.9999) 
respectively and above-mentioned values were summarized in table 2. 
  
 
Fig. 3: Calibration curve of canagliflozin at 214 nm wavelength 
 
Table 2: Linearity results 
Conc (μg/ml) *Mean peak area±SD (% RSD) 
0 0 
2 119239±313.27 (0.26) 
4 241205±447.42 (0.19) 
6 357247±745.82 (0.21) 
8 477162±1129.36 (0.24) 
10 598350±1692.10 (0.28) 
12 718368±1613.80 (0.22) 
20 1199824±3259.30 (0.26) 
40 2472039±6337.27 (0.26) 
80 4877656±11126.12 (0.23) 
100 6021517±10327.08 (0.17) 
120 7293651±14646.85 (0.20) 
 Data expressed as mean±SD; n=3. 
 
The percentage Recovery studies for Canagliflozin is 99.70, 
98.54 and 99.21 for 80%, 100% and 120 % and these results are 
within acceptable limit of 98-102. And its high value of 
recoveries at different concentrations indicates the proposed 
method is accurate. The accuracy data of the proposed method is 
summarized in table 3. 
Arulselvan M. & M. M. Annapurna 
Int J App Pharm, Vol 13, Issue 5, 2021, 358-363 
361 
Table 3: Accuracy and precision studies of canagliflozin 
Spiked conc (μg/ml) Total conc (μg/ml) *Mean peak area±SD (%RSD) Drug found (μg/ml) % Recovery 
3.2 (80%) 7.2 433911±680.38(0.16) 7.18 99.70 
4 (100 %) 8 476535±604.22 (0.13) 7.88 98.54 
4.8 (120%) 8.8 527758±804.35 (0.15) 8.73 99.21 
Concentration (μg/ml) Intra-day Inter-day 
*Mean peak area±SD % RSD *Mean peak area±SD % RSD 
4 241531±347.10  0.14 241349±329.74 0.14 
8 484159±833.90 0.17 483258±582.35 0.12 
12 733163±1266 0.17 733177±1082.75 0.15 
Data expressed as mean±SD; n=3. 
 
Precision is measured by injecting three replicates of standard 
solutions (4μg/ml, 8μg/ml and 12μg/ml concentration) within a day 
at a different time interval. The intra-day and inter-day precision 
studies (intermediate precision) were carried out. The % RSD values 
of Intra-day and Inter-day for Canagliflozin are less than 2% (Intra-
day 0.14 to 0.17, Inter-day 0.12 to 0.15) which reveal that the 
proposed method is precise table 3. 
Robustness of the method was studied by varying the flow rate, 
detector wavelength, Column temperature, and change in mobile 
phase composition within the limited parameter. No palpable 
change in mean retention time (Rt), mean % assay and %RSD and 
also assay results are within the acceptable limit of ≤ 2. The tailing 
factor and plate count were found to be in acceptable limits 
i.e.,>2500 and<2.0, respectively. The % RSD obtained was 0.10-0.17 
for Canagliflozin, which is less than 2.0%, indicating the proposed 
method is Robust. Summary of robustness report under different 
conditions (change in flow rate, temperature and wavelength) were 
summarized in table 4. 
 
Table 4: Result of robustness method canagliflozin (4µg/ml) 
S. No. Parameters Condition *Mean peak area *Mean peak area±SD (% RSD) 
1 Flow rate (0.8 ml/min) 240928 241186±286 (0.12) 
2 Flow rate (1.0 ml/min) 241494 
3 Flow rate (1.2 ml/min) 241136 
4 Wavelength 212 nm 241199 241378±158 (0.10) 
5 Wavelength 214 nm 241435 
6 Wavelength 216 nm 241499 
7 Temperature 28 °C 242063 241627±381 (0.15) 
8 Temperature 30 °C 241458 
9 Temperature 32 °C 241359 
10 Mobile phase (55: 45) 242199 241720±421 (0.17) 
11 Mobile phase (57: 43) 241409 
12 Mobile phase (59: 41) 241553 
Data expressed as mean±SD; n=3. 
 
Analysis of marketed formulation 
The Content of Canagliflozin in the PROMINAD 100 mg tablets was 
determined by the proposed analytical method. The assay value 
calculated by assaying 6 samples of the Canagliflozin, the percentage 
value found to be 99.92 with Standard deviation 0.1 and % relative 
standard deviation of 0.14. The mean concentration of Canagliflozin 
in the given sample PROMINAD was found to be 99.92 mg (99.92%). 
The obtained assay values are within the acceptable limit (98-102%) 
against the amount claimed in the label table 5. 
Stress degradation studies  
As per the guidelines of ICH, stressed degradation studies were 
conducted to identify the degradation products and also ability of 
the drug to withstand the different physical and chemical 
conditions. A stability study provides information about the 
standard and degradation products of Canagliflozin. From the 
stressed stability studies, it was clear that the drug withstands 
chemical parameters such as acid hydrolysis, alkaline hydrolysis 
and oxidation. At the same time high amount of degradation was 
observed in the sample kept on irradiation with UV light. Typical 
chromatograms obtained following the assay of stress sample are 
shown in fig. 4. The concentration of the obtained degradation 
products analogous to the standard Canagliflozin was calculated 
and reported to be acidic (16.47%), alkaline (7.74%), Oxidative 
(16.05%), Thermal (16.53%) and Photolytic (16.56%) in case of 
acid hydrolysis, alkaline hydrolysis, oxidation, thermal and 
photolytic stability respectively table 6. 
 
Table 5: Assay estimation of canagliflozin in prominad 
Formulation Labeled claim (mg) Amount found* (mg) Recovery*(%) 
Prominad 100 99.92 99.92 
 Data expressed as mean±SD; n=6. 
 
Table 6: Data of stress degradation studies canagliflozin (40µg/ml) 
Stress condition *Mean peak area *Drug recovered (%) *Drug decomposed (%) Theoretical plate Tailing factor 
Standard drug (untreated) 2413068 100 - 2753 0.998 
Acidic degradation 2015648 83.53 16.47 2711 1.012 
Alkaline degradation 2226327 92.26 7.74 2891 0.991 
Oxidative degradation 2025698 83.95 16.05 2867 1.010 
Thermal degradation 2014175 83.47 16.53 2910 1.015 
Photolytic degradation 2013524 83.44 16.56 2887 1.022 
Data expressed as mean±SD; n=3. 
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Fig. 4: Chromatogram of canagliflozin in photolytic degradation A-Blank, B-Standard, C-Acidic, D-Alkaline, E-Oxidative, F-Thermal, G-
Photolytic degradation 
 
In this research work the developed methods can be adopted for the 
determination of Gliflozin derivatives with common solvent system 
which utilizes low % organic solvents with a higher retention rate 
continually. Chromatographic separation of Canagliflozin using RPHPLC 
parameters have been optimized and validated as per ICH guidelines 
with aid of utilizing various % compositions of organic solvents as 
mobile phase. Persistent Retention time with higher retention rate and 
good peak symmetry for Canagliflozin obtained with ACN: H2O (53:47 % 
v/v) at a flow rate of 1 ml/min at 214 nm. Retention time was found to 
be 2.36 min Incessant of this Retention time assures the uniqueness of 
our method compared to various reported methods by researchers [8-
14]. Based on statistical evidence of Linearity, accuracy and Precision, 
the % RSD values regret that our method is Unique, specific, sensitive 
and accurate for the assay of Canagliflozin.  
CONCLUSION 
The research work initiate to be promising and less time-consuming 
with minimum amount of solvent utilization for method 
development compared to previous submitted research work. The 
developed method proved that the method is specific, accurate, 
precise, rugged and robust for Gliflozin derivatives. Stress 
degradation studies revealed that Canagliflozin withstands the 
acidic, alkaline, oxidation condition at the same time Photolytic 
degradation occurs over a period of time if the drug is exposed to UV 
radiation. The developed method and obtained statistical data 
manifested that designed protocol is simple, rapid and economical 
for estimation of Canagliflozin API and pharmaceutical formulation. 
ACKNOWLEDGEMENT 
The authors felt grateful and happy the way we received support 
from Anjuman-I-Islam Kalsekar Technical Campus School of 
Pharmacy, allowing us to conduct the research work in their Central 




All authors have contributed equally. 
CONFLICT OF INTERESTS 
Declared none 
REFERENCES 
1. Harsharan PS, Ishpreet K, Gunjan S. Sodium-glucose co-
transporters-2 (SGLT2) inhibitors as a new class of anti-
diabetic drugs: pharmacokinetics, efficacy and clinical 
significance. Int J Pharm Sci Rev Res 2015;33:40-7.  
2. Wright EM, Turk E. The sodium/glucose co-transport family 
SLC5. Pflugers Arch 2004;447:510-8. 
3. Nair S, Wilding JP. Sodium-glucose co-transporter 2 inhibitors 
as a new treatment for diabetes mellitus. J Clin Endocrinol 
Metab 2010;95:34-42. 
4. Misra M. SGLT2 inhibitors: a promising new therapeutic option 
for treatment of type 2 diabetes mellitus. J Pharm Pharmacol 
2013;65:317-27. 
5. Strojek K, Yoon KH, Hruba V. Effect of dapagliflozin in patients 
with type 2 diabetes who have inadequate glycaemic control 
with glimepiride: a randomized, 24-week, double-blind, placebo-
controlled trial. Diabetes Obesity Metab 2011;13:928-38. 
6. Kim Y, Babu AR. Clinical potential of sodium-glucose 
cotransporter 2 inhibitors in the management of type 2 diabetes. 
Diabetes Metabolism Syndrome Obesity 2012;5:313-27. 
7. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/
204042Orig1s032TOC.cfm [Last accessed on 02 Jan 2021] 
8. Muzaffar I, Nasr YK, Amer MA, Khalid A Al-R. A simple and 
sensitive high-performance liquid chromatography assay with 
a fluorescence detector for determination of canagliflozin in 
human plasma. Anal Methods 2015;7:3028-35.  
9. Suneetha, D Sharmila. A validated stability indicating RP-HPLC 
method for estimation of canagliflozin in dosage form. Res J 
Pharm Biol Chem Sci 2015;6:1186-94. 
10. Ishpreet K, Sharad W, Harsharan PS, Satish M. Development 
and validation of a stability-indicating reverse phase HPLC-
PDA method for determination of canagliflozin in bulk and 
pharmaceutical dosage form. Pharm Methods 2016;7:54-62. 
11. Sonia D, Muddu K, Gude SS, Vasantharaju SG. Stability 
indicating assay method development and validation to 
simultaneously estimate metformin hydrochloride and 
canagliflozin by RP-HPLC. Curr Trends Biotechnol Pharm 
2016;10:334-42. 
12. Deepak G, Patil RN, Mangesh H. A validated stability-indicating 
RP-HPLC method for simultaneous determination of metformin 
and canagliflozin in pharmaceutical formulation. World J 
Pharm Pharm Sci 2015;4:631-40. 
13. Uttam PP, Sunil KR. A novel validated RP-HPLC-DAD method 
for the simultaneous estimation of metformin hydrochloride 
and canagliflozin in bulk and pharmaceutical tablet dosage 
form with forced degradation studies. Orient J Chem 
2015;31:1489-507. 
14. Nareddy PR, Naga TC. RP-HPLC method development and 
validation for the simultaneous estimation of metformin and 
canagliflozin in tablet dosage form. Int J Pharm Sci 
2015;5:1155-9. 
15. Muzaffar I, Nasr YK, Amer MA, Khalid A. A simple and sensitive 
high performance liquid chromatography assay with a 
fluorescence detector for determination of canagliflozin in 
human plasma. Anal Methods 2015;7:3028-35. 
Arulselvan M. & M. M. Annapurna 
Int J App Pharm, Vol 13, Issue 5, 2021, 358-363 
363 
16. Ishpreet K, Sharad W, Harsharan PS. Development and 
validation of a stability-indicating high-performance thin-layer 
chromatography (HPTLC) method for estimation of 
canagliflozin in bulk and pharmaceutical dosage form. J Appl 
Pharm Sci 2016;6:51-7. 
17. Ishpreet K, Sharad W, Harsharan PS, Satish M. Development 
and validation of UV spectroscopic method for determination 
of canagliflozin in bulk and pharmaceutical dosage form. 
Pharmaceutical Methods 2015;6:82-6. 
18. Nirali DP, Darshil BS, Dilip GM. Development and validation of 
UV spectrophotometric estimation of canagliflozin in its 
pharmaceutical dosage form. Int J Pharm Technol 
2015;7:9779-84. 
19. Iqbal M, Ezzeldin E, Al-Rashood KA. Rapid determination of 
canagliflozin in rat plasma by UHPLC–MS/MS using negative 
ionization mode to avoid adduct-ions formation. Talanta 
2015;132:29-36. 
20. Dudhe PB, Kamble MC. RP-HPLC method development and 
validation for the determination of canagliflozin in human 
plasma. Int J Pharm Res Technol 2016;9:174-81. 
21. Kobuchi S, Yano K, Ito Y, Sakaeda T. A validated LC-MS/MS 
method for the determination of canagliflozin, a sodium-
glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume 
of rat plasma: application to pharmacokinetic studies in rats. 
Biomed Chromatography 2016;30:1549-55. 
22. ICH guideline Q1A (R2). Stability testing of new drug 
substances and products. ICH; 2003. Available from: 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Product
s/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf 
[Last accessed on 02 Jan 2021] 
23. ICH guideline Q2 (R1). Validation of analytical procedures: text and 
methodology. ICH. 2005. Available from: http://www.ich.org/ 
fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Quality/ 
Q2_R1/Step4/Q2_R1__Guideline.pdf [Last accessed on 02 Jan 
2021]. 
 
